

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9960)

POSITIVE PROFIT ALERT

This announcement is made by Kindstar Globalgene Technology, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of The Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders and potential investors of the Company that, based on the Group’s unaudited consolidated management accounts for the six months ended June 30, 2022 (“**1H2022**”) and other information currently available to the Board, the total revenue of the Group for 1H2022 is expected to be within the range of RMB613 million to RMB660 million, representing an increase of approximately 40% to 50% as compared to the total revenue of the Group of approximately RMB438.2 million for the six months ended June 30, 2021. Meanwhile, the Group is also expected to turn losses into profits for 1H2022 as compared to the corresponding period of 2021. The Company will make appropriate announcement as to the specific amount of the expected profit for 1H2022 in due course.

The improvements in the Group’s financial results were mainly due to the fact that:

- i) the Group spared no effort to minimize the severe impact of COVID-19 pandemic in some cities in China, including Shanghai. As a result, the Group’s specialty esoteric testing services still grew steadily despite the renewal of COVID-19 pandemic in 1H2022;
- ii) there was no substantial fair value loss on financial liabilities at fair value through profit or loss (FVTPL) comparing with the corresponding period of 2021; and
- iii) the Group’s COVID-19-related testing segment achieved substantial growth with more frequent testing in some cities in China because of the renewal of COVID-19 pandemic in 1H2022.

The Company is still in the process of finalizing the interim results of the Group for 1H2022. The information contained in this announcement is only based on the preliminary assessment by the Board according to the unaudited consolidated management accounts of the Group for 1H2022 and the currently available information, which have not been audited or reviewed by the Company's auditor or the audit committee of the Company, and may be subject to further adjustments and may differ from the figures to be disclosed in the interim results announcement of the Company for 1H2022 (the “**Interim Results Announcement**”). Shareholders and potential investors of the Company should read carefully the Interim Results Announcement, which is expected to be published by the end of August 2022 in accordance with the requirements of the Listing Rules.

Shareholders and potential investors of the Company are advised not to place any reliance on the information disclosed herein but to exercise due caution when dealing in the securities of the Company. When in doubt, shareholders and potential investors of the Company are advised to seek professional advice from professional or financial advisers.

By order of the Board
Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
HUANG Shiang
Chairman

Hong Kong, July 20, 2022

As of the date of this announcement, the Board comprises Dr. Huang Shiang, Mr. Tu Zanbing and Ms. Chai Haijie as executive Directors, Mr. Huang Zuie-Chin, Mr. Peng Wei and Ms. Huang Lu as non-executive Directors, and Dr. Yao Shanglong, Dr. Xia Xinping and Mr. Gu Huaming as independent non-executive Directors.